in vivo data before tweaking in vitro [Dissolution / BCS / IVIVC]

posted by Kiran – 2017-06-24 22:19 (2496 d 07:25 ago) – Posting: # 17502
Views: 7,625

Hello Mr.Helmut,

Firstly very thankful for your quick response.

Your input is valid but the thing is the dissolution method in which my generic product is faster is given in the FDA guidance and I am bound to meet f2 value w.r.t to that of the reference product.

One more thing is that the drug shows local action in the gut so invitro profile is more relevant to show comparison with that of the reference product.

The main reason I am presuming is the variation in the solubility of drugs in reference and test product to be the major reason for the variation in the dissolution profile due to polymorphic difference.The drug in the reference product has low solubility.

Regards,
Kiran.


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,656 registered users;
107 visitors (0 registered, 107 guests [including 3 identified bots]).
Forum time: 05:45 CEST (Europe/Vienna)

Never never never never use Excel.
Not even for calculation of arithmetic means.    Martin Wolfsegger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5